Platelet Aggregation Devices Market: Global Analysis & Outlook (2018-2023) - Technological Advancements in Platelet Aggregometers; a Key Driver - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 22, 2018--The “Global Platelet Aggregation Devices Market - Segmented by Product (Systems, Reagents, Consumables and Accessories), Application, End User and Geography - Growth, Trends and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The Global Platelet Aggregation Devices Market is projected to grow at a CAGR of approximately 19% during the forecast period (2018-2023).
Technological Advancements in Platelet Aggregometry
Traditional LTA remains the most useful technique for diagnosing a wide variety of platelet defects. The main disadvantage of LTA is the use of PRP instead of the whole blood under relatively low shear conditions, and, in the absence of red and white cells, it does not accurately simulate primary hemostasis.
Additionally, LTA requires large sample volume, is time-consuming, and there are many pre-analytical and analytical variables that affect the LTA results. These shortcomings in traditional aggregometry spurred the development and advancement of aggregometry techniques which are widely being adopted in the current market.
The platelet function analyzers (PFA) are the result of such developments. The platelet function tests performed through a PFA are automated, rapid and mimic several characteristics of physiologic platelet function, because it is a high shear system. Additionally, PFA makes use of whole blood samples instead of PRP.
Consequently, the advancements in aggregometry are improving the adoption rate of these devices and in turn helping in the growth of the Global Platelet Aggregation Devices Market.
Procedural Limitations in Pediatrics
One of the major limitations of light transmission aggregometry (LTA) is that the method is time- and labor-intensive and requires a large volume of blood. The latter presents significant challenges when platelet function needs to be assessed in pediatric patients, in whom the volume of blood sample is usually very limited.
To overcome these limitations, various high throughput methods are being developed to measure platelet aggregation in PRP using lyophilized reagents which offers simultaneous assessment of several platelet activation pathways in a smaller volume of PRP. These throughput methods might be useful in the future as a screening tool that can be available in non-specialized laboratories once this test is validated further and becomes commercially available.
But in the current market, the limitations of LTA especially in pediatrics is causing significant hindrance to market growth. Additionally, the issue of low blood samples in pediatrics is further compounded by the short shelf life of PRP. PRP sample once prepared needs to be kept in temperature controlled environment and it cannot be stored for more than a couple of hours, even in most suitable conditions, after which aggregation is auto-induced due to platelet activation, rendering the PRP useless for platelet function testing.
North America Accounted for Largest Market Share
The North America region accounted for the largest market share in the Global Platelet Aggregation Devices Market, in 2017. North America is also expected to show highest growth over the forecast period.
The largest market share of North America can be attributed to the strong presence of device manufacturers in the region, growing number of surgical procedures, and rising awareness among healthcare professionals regarding the benefits offered by platelet aggregation testing in disease diagnosis.
Additionally, factors like large number of patients undergoing cardiovascular surgeries, and increasing prevalence of orthopedic, urological, and bleeding disorders are expected to sustain the market leader status of North America supported by high growth rate.
Industry DevelopmentsAbcam, a global innovator in life science reagents and tools, and Molecular Devices, LLC, a leading provider of high-performance bioanalytical measurement solutions, announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.
DriversGlobally Increasing Geriatric Population Technological Advancements in Platelet Aggregometers Increasing Number of Industry-Academia Collaborations and Clinical Studies
RestraintsProcedural Limitations Dearth of Well-Trained, Skilled, and Experienced Professionals
OpportunitiesPoint-Of-Care Diagnostics & Miniaturized Platelet Aggregometers
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview 5.1 Current Market Scenario 5.2 Porter’s Five Forces Analysis
6. Market Dynamics 6.1 Drivers 6.2 Restraints 6.3 Opportunities 6.4 Challenges
7. Market Segmentation 7.1 By Product 7.2 By Application 7.3 By End User 7.4 By Geography
8. Company Profiles & Competitive Landscape 8.1 Accriva Diagnostics Holdings Inc. 8.2 Aggredyne Inc. 8.3 Bio/Data Corporation 8.4 F. Hoffman-La Roche Ltd. 8.5 Haemonetics Corporation 8.6 Helena Laboratories Corporation 8.7 Sentinel Ch. S.P.A. 8.8 Siemens AG 8.9 Sysmex Corporation 8.10 TEM Group *List Not Exhaustive
9. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/z53lx6/platelet?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181122005212/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Medical Devices
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY HEALTH MEDICAL DEVICES GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 11/22/2018 07:34 AM/DISC: 11/22/2018 07:34 AM